[Pharmacological profile and clinical findings on varenicline tartrate (Champix tablets)].
Hizue
Masanori
M
masanori.hizue@pfizer.com
Ishibashi
Taro
T
Nomura
Shunji
S
D000818:Animals; D001552:Benzazepines / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003342:Corpus Striatum / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D009538:Nicotine / Q000494:pharmacology; D018722:Nicotinic Agonists / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D009714:Nucleus Accumbens / Q000378:metabolism; D011810:Quinoxalines / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D011978:Receptors, Nicotinic / Q000378:metabolism; D016540:Smoking Cessation; D014029:Tobacco Use Disorder / Q000188:drug therapy*; D000068580:Varenicline
D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D011978:Receptors, Nicotinic; D009538:Nicotine; D004298:Dopamine; D000068580:Varenicline